| Submit your comments on this article |
| Science & Technology |
| Revolutionary Israeli bone marrow transplant method meets trial goals |
| 2020-12-13 |
| [JP] Israel-based Gamida Cell Ltd. announced this week that its phase III study of Omidubicel had met all of its primary and secondary goals regarding key clinical measures in bone marrow transplants. The company also announced that it is prepared with a commercial model for Omidubicel that will include a support system for patients and families called Gamida Cell Assist. The primary goal that was met in the third phase of the trial was estimating the time from transplant of Omidubcel to the reception of neutrophils, a type of blood cell that leads the body's immune system's response. The amount of time was 12 days compared to 22 days in the control group. Additionally, the trial met all of its secondary goals. Of patients treated with the Omidubcels, 37% developed infections that were moderate or severe compared to 57% of the control group in the 100 days following transplant. Omidubcel recipients spent 60.5 days out of the hospital in the 100 days following treatment compared to 48 days in the control group. |
| Posted by:Besoeker |